Pharmacologic profile of the adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 2, 2014, Pages 412-424

  Mitchell, Tracy ^a   Chao, Ginger ^a   Sitkoff, Doree ^a   Lo, Fred ^a   Monshizadegan, Hossain ^a   Meyers, Daniel ^a   Low, Simon ^a   Russo, Katie ^a   DiBella, Rose ^a   Denhez, Fabienne ^a   Gao, Mian ^a   Myers, Joseph ^a   Duke, Gerald ^a   Witmer, Mark ^a   Miao, Bowman ^a   Ho, Siew P ^a   Khan, Javed ^a   Parker, Rex A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 962476; LOW DENSITY LIPOPROTEIN; MACROGOL; PEGDINETANIB; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROTEIN INHIBITOR; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOTINYLATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DOWN REGULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GEL PERMEATION CHROMATOGRAPHY; HEMIZYGOSITY; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CRYSTALLIZATION; FEMALE; HUMANS; LIPOPROTEINS, LDL; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; PROPROTEIN CONVERTASES; PROTEINS; RATS; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SPECIES SPECIFICITY;

EID: 84905001697     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214221     Document Type: Article

References (43)

1. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, and Erlich D, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156.
2. Benjannet S, Saavedra YG, Hamelin J, Asselin MC, Essalmani R, Pasquato A, Lemaire P, Duke G, Miao B, and Duclos F, et al (2010) Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem 285:40965-40978.
3. Bottomley MJ, Cirillo A, Orsatti L, Ruggeri L, Fisher TS, Santoro JC, Cummings RT, Cubbon RM, Lo Surdo P, and Calzetta A, et al. (2009) Structural and biochemical characterization of the wild type PCSK9/EGF-AB complex and natural familial hypercholesterolemia mutants. J Biol Chem 284:1313-1323.
4. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484.
5. Bendele A, Seely J, Richey C, Sennello G, and Shopp G (1998) Short Communiction: Renal tubular vacuolation in animals treated with polyethelene-glycol-conjugated proteins. Toxicol Sci 42:152-157.
6. Chan JC, Piper DE, Caoa Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, and Xia Z, et al. (2009) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 106:9820-9825.
7. Choi S, Aljakna A, Srivastava U, Peterson BR, Deng B, Prat A, and Korstanje R (2013) Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Lipids Health Dis 12:112-121.
8. Cohen JC, Boerwinkle E, Mosley T.H., Jr, and Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272.
9. Doyle ML (1997) Characterization of binding interactions by isothermal titration calorimetry. Curr Opin Biotechnol 8:31-35.
10. Drake AW, Myszka DG, and Klakamp SL (2004) Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem 328:35-43.
11. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
12. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt A, Sutherland J, Hutabarat R, Clausen V, Karsten V, and Cehelsky J, et al. (2013) Effect of an RNA interference drug on the synthesis of PCSK9 and concentration of serum LDL cholesterol in healthy volunteers: phase 1 trial. Lancet 383:60-68.
13. Gilbreth RN, Truong K, Madu I, Koide A, Wojcik JB, Li N-S, Piccirilli JA, Chen Y, and Koide S (2011) Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design. Proc Natl Acad Sci USA 108:7751-7756.
14. Graham M, Lemonidis K, Whipple C, Subramaniam A, Monia B, Crooke S, and Crooke R (2008) Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48:763-767.
15. Grefhorst A, McNutt MC, Lagace TA, and Horton JD (2008) Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 49:1303-1311.
16. Ha YC and Barter PJ (1985) Rapid separation of plasma lipoproteins by gel permeation chromatography on agarose gel Superose 6B. J Chromatogr A 341:154-159.
17. Horton JD, Cohen JC, and Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32:71-77.
18. Gordon V, Innerarity TL, and Mahley RW (1983) Formation of cholesterol- and apoprotein E-enriched high density lipoproteins in vitro. J Biol Chem 258:6202-6212.
19. Koide A, Bailey CW, Huang X, and Koide S (1998) The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 284:1141-1151.
20. Kubetzko S, Sarkar CA, and Plückthun A (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 68: 1439-1454.
21. Kwon HJ, Lagace TA, McNutt MC, Horton JD, and Deisenhofer J (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 105:1820-1825.
22. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, and Horton JD (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116: 2995-3005.
23. Lakoski SG, Lagace TA, Cohen JC, Horton JD, and Hobbs HH (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 94: 2537-2543.
24. Leahy DJ, Aukhil I, and Erickson HP (1996) 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 84:155-164.
25. Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, and Yu J, et al. (2012) Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hyper-cholesterolemic nonhuman primates. J Pharmacol Exp Ther 340:228-236.
26. Lipovsek D (2011) Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 24:3-9.
27. Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, and Carfí A (2011) Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 12: 1300-1305.
28. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40:658-674.
29. Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, Pandit S, Hammond HA, Rosa R, and Cummings RT, et al. (2011) A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 52:78-86.
30. Parker MH, Chen Y, Danehy F, Dufu K, Ekstrom J, Getmanova E, Gokemeijer J, Xu L, and Lipovsek D (2005) Antibody mimics based on humanfibronectin type-three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor two. Protein Eng Des Sel 18:435-444.
31. Parker RA, Garcia R, Ryan CS, Liu X, Shipkova P, Livanov V, Patel P, and Ho SP (2013) Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. J Lipid Res 54:2400-2409.
32. Pflugrath JW (1999) The finer things in X-ray diffraction data collection. Acta Crystallogr D Biol Crystallogr 55:1718-1725.
33. Ramamurthy V, Krystek SR, Jr, Bush A, Wei A, Emanuel SL, Das Gupta R, Janjua A, Cheng L, Murdock M, and Abramczyk B, et al. (2012) Structures of adnectin/protein complexes reveal an expanded binding footprint. Structure 20:259-269.
34. Rudmann DG, Alston JT, Hanson JC, and Heidel S (2013) High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol 41:970-983.
35. Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, and Prat A (2008) The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 40:1111-1125.
36. Seidah NG and Prat A (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11:367-383.
37. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, and Wu R, et al (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366:1108-1118.
38. Stein EA and Raal FJ (2013) Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. Circulation 127:2372-2374.
39. Steinberg D and Witztum JL (2009) Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA 106:9546-9547.
40. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, and Fazio S (2013) Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 127: 2403-2413.
41. Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, and Koide S (2010) A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol 17:519-527.
42. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, and Hobbs HH (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282:18602-18612.
43. Zhang Y, Eigenbrot C, Zhou L, Shia S, Li W, Quan C, Tom J, Moran P, Di Lello P, and Skelton NJ, et al. (2014) Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem 289:942-955.